XML 22 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenues:    
Research and development revenue $ 2,403,831 $ 1,601,921
Costs and expenses:    
Costs of research and development revenue 1,944,438 1,424,931
Provision for contract losses 0 187,388
Research and development 8,392,370 3,868,121
General and administrative 6,697,617 6,084,799
Foreign currency exchange loss 96,893 62,345
Total costs and expenses 17,131,318 11,627,584
Loss from operations (14,727,487) (10,025,663)
Other income:    
Interest income 51,704 446,999
Gain from the sale of investments in BDI 1,605,532 0
Unrealized gain from investment in Alphazyme 0 284,709
Total other income 1,657,236 731,708
Loss before income taxes (13,070,251) (9,293,955)
Provision for income taxes 0 31,318
Net loss $ (13,070,251) $ (9,325,273)
Basic and diluted net loss per common share (in dollars per share) $ (0.47) $ (0.34)
Basic and diluted weighted-average common shares outstanding (in shares) 27,838,047 27,471,587